Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$157,600.00
Oct 1, 2012
Cancer vaccines targeting the ganglioside tumor-marker GD2
$159,097.00
Oct 1, 2012
Commercialization of a Radiopaque Spherical Embolic Agent.
$84,204.00
Oct 1, 2012
Assessing the Ethics of the Dominant Business Model in the Canadian Pharmaceutical Sector; Tackling Institutional Corruption through Regulatory Reforms
$159,149.00
Oct 1, 2012
Développement de composés antinéoplasiques radiosensibilisants acheminés par nano transporteur liposomal.
$357,714.00
Oct 1, 2012
Development of an anti-proliferative therapeutic that disrupts CaM-cyclin E interactions in vivo.
$100,000.00
Oct 1, 2012
Establishing a New Research Agenda Regarding Population Health Ethics and Young People's Health
$160,000.00
Oct 1, 2012
Benchmark Cellax, a proprietary nanoparticle formulation for docetaxel, against Taxotere to treat metastatic castration resistant prostate cancer
$156,060.00
Oct 1, 2012
A-CD estrogens as alternatives to Estrogen-based hormone replacement therapy
$159,252.00
Oct 1, 2012
Total liquid ventilation improves respiratory and neurological outcomes in newborn lambs with severe respiratory failure
$103,153.00
Oct 1, 2012
A novel point-of-care method of handling human waste in healthcare institutions: technical improvements and evaluation.